SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Julian who wrote (905)5/5/2000 2:58:00 PM
From: Ian@SI  Read Replies (1) of 1321
 
Julian,

QLT sticking with its revenue guidance of $14M-$15M for the current quarter even though the FDA approval was delayed. Sounds as if they're lowballing it somewhat.

To me this implies that the Revenue / Earnings growth in the last 1/2 of the year could be significantly stronger than currently expected.

Lasers have been installed at 250 sites with about 800 Retinal Specialists trained in the process.

Substantial interest was seen in the sessions at ARVO.

European approval is happening faster than expected - which should be another upside adjustment to earnings possibly as soon as 3Q2000.

And all US retinal specialists will have their initial complement of lasers this quarter - 2 Qs ahead of schedule.

All in all, looking very good from a fundamental perspective.

Now for the market to recognize those facts in the price. ;-)

Best wishes,
Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News